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Abstract
Programmed cell death 5 (PDCD5) is a cytosolic protein suppressing growth of multiple types of cancer cells through
activating p53. We hypothesized that PDCD5 plays an essential role in cardiac remodeling and function. PDCD5 was
significantly up-regulated in the hearts from mice subjected to angiotensin II treatment or transverse aortic constriction.
Thus, we generated transgenic mice over-expressing human PDCD5 under the control of alpha myosin heavy chain
promoter to examine the role of PDCD5 in cardiac remodeling. Transgenic founder died spontaneously displayed enlarged
heart. The high PDCD5 over-expressing line (10-fold) showed reduced survival rate, increase in heart weight normalized to
body weight. Real-Time RT-PCR analysis revealed fetal gene program was up-regulated. Echocardiography and
histopathological examination showed characteristics of dilated cardiomyopathy and heart failure in transgenic mice.
Western blot and immunohistochemistry analysis showed autophagy was dramatically increased in transgenic mice as
compared to WT littermates control mice, while apoptosis remained unchanged. The enhanced autophagy in high over-
expressing line was associated with significant increase in p53 activity and its downstream target damage-regulated
autophagy modulator expression. The low over-expressing line (3.5-fold) appeared normal, but was more susceptible to
angiotensin II-induced cardiac hypertrophy. This study is the first providing evidence that PDCD5 plays an important role in
cardiac remodeling.
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Introduction
Programmed cell death 5 (PDCD5) was initially cloned from
apoptotic TF-1 cells and currently known as a tumor suppressor
candidate [1–4]. PDCD5 is up-regulated in various cells
undergoing apoptosis and translocated from cytosol to nucleus to
execute its apoptotic function [5]. Apoptotic potential of PDCD5
is linked with CK2 phosphorylation [6]. A recent study
demonstrates that PDCD5 positively regulates Tip60, a transcrip-
tional coregulator, which in turn, promotes p53 acetylation,
leading to enhanced p53-dependent apoptosis [7]. It has also been
shown that PDCD5 can enhance TAJ/TROY–induced para-
ptosis–like cell death [8]. In addition, PDCD5 plays an important
role in the pathogenesis of rheumatoid arthritis [9–10]. However,
nothing is known about the role of PDCD5 in cardiac remodeling
and function.
Macroautophagy (refer to here as autophagy) is a highly
conserved process of bulk protein degradation by lysosomes.
Under basal or certain stress conditions such as nutrient starvation,
autophagy promotes cell survival by eliminating misfolded proteins
and organelles and provides energy and amino acids for the cells
[11–12]. However, excessive levels of autophagy lead to
autophagic cell death [13–15]. A growing body of evidence has
shown that enhanced autophagy is associated with numerous
diseases such as cancer, neurodegenerative disorders, myopathies
and infectious deseases [16–17]. Recent studies demonstrate that
dysregulation of autophagy contributes to the pathogenesis of
many forms of heart diseases and its function is dose and context
dependent [18–22]. Autophagy can be induced by a number of
stimuli and regulated by multiple signaling pathways including p53
[11–12,23–25]. Regulation of autophagy by p53 is dependent on
its subcellular localization [23]. On the one hand, nucleus p53
stimulates autophagy through transcriptional effects including
transactivation of damage-regulated autophagy modulator
(DRAM) [24]. On the other hand, cytoplasmic pool of p53
represses autophagy through poorly characterized mechanisms
[25]. Given the regulatory associations between PDCD5, p53 and
autophagy, we hypothesize that PDCD5 is essential for cardiac
remodeling and function through regulating autophagy.
In this study, we created transgenic mice with cardiac specific
over-expression of human PDCD5 to investigate the role of
PDCD5 in cardiac remodeling and function. We found that
myocardial high PDCD5 over-expression results in dilated
cardiomyopathy and heart failure accompanied by dramatically
enhanced autophagy, which is associated with increased p53
activity. Transgenic mice with low over-expression of PDCD5 are
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30097more susceptible to angiotensin II (Ang II)-induced cardiac
hypertrophy. Our study provides the first evidence that PDCD5
contributes to the cardiac remodeling and function through
upregulating autophagic activity.
Results
PDCD5 is up-regulated in cardiac hypertrophy
Previous study showed that PDCD5 mRNA was expressed at
considerable levels in adult heart [1]. To determine whether
PDCD5 may be involved in cardiac remodeling, we first examined
PDCD5 protein levels in heart extracts from adult mice subjected
to 2-week Ang II treatment. In this hypertrophic model, the heart-
to-body weight ratio was significantly increased in Ang II-treated
mice (5.360.1, n=15) compared to sham control (4.760.1,
n=12; p,0.01) (Fig. 1A). Atrial natriuretic factor (ANF) and beta
myosin heavy chain (bMHC), two molecular markers for cardiac
hypertrophy, were significantly increased in Ang II-treated mice
(Fig. 1B–C). Assessment of PDCD5 protein expression levels
showed significant elevation in Ang II-induced hypertrophied
hearts (Fig. 1D–E). Similarly, PDCD5 protein was significantly
increased in heart from mice subjected to acute pressure overload
for 2 weeks by transverse aortic constriction (Figure S1A–B).
These data suggest PDCD5 may be involved in cardiac
remodeling.
Generation of alpha-MHC-hPDCD5 transgenic mouse line
To define the potential role of PDCD5 in cardiac remodeling,
we generated transgenic mice over-expressing human PDCD5
under the control of alpha myosin heavy chain promoter (Fig. 2A),
which directs expression specifically to postnatal ventricular
cardiomyocytes [26–28]. Five founders identified by PCR
genotyping were maintained to generate transgenic lines. Two
founders (number 19 and number 41) died spontaneously before
successful mating. Autopsy of founder 41 showed enlarged heart
(Fig. 3A). One founder (number 39) was not able to transmit
transgene to the next generation. Founder 32 and founder 50
successfully produced progeny positive for the presence of
transgene. Western blot with PDCD5 polyclonal antibody
revealed hPDCD5 protein abundance was 10-fold higher (high
over-expressing line) compared to endogenous PDCD5 protein in
transgenic line 32 (Fig. 2B–C). Accordingly, Real-Time RT-PCR
showed significant increase in PDCD5 mRNA in high over-
expressing line (Figure S2). Furthermore, western blot with anti-
HA antibody detected hPDCD5-HA fusion protein in heart
(Fig. 2D), but not in other tissues such as liver and brain (Fig. 2E).
In transgenic line 50, PDCD5 protein abundance was increased by
3.5 folds (low over-expressing line) in hearts as revealed by western
blot analysis (Figure S3A). The heart-to-body weight ratio and
cardiac function were comparable to WT littermate control mice
(Figure S3B–C, Table S1).
Figure 1. Up-regulation of PDCD5 in Ang II-induced cardiac hypertrophy. (A), HW:BW ratio showing significant increase in cardiac mass in
mice treated with Ang II for 2 weeks compared to sham control mice. (B) Expression of ANF was determined by quantitative Real-Time RT-PCR
analysis in cDNA samples derived from hearts of mice treated with Ang II and sham control. (C), Expression of bMHC was determined by quantitative
Real-Time RT-PCR analysis in cDNA samples derived from hearts of mice treated with Ang II and sham control. (D), Representative western blot of
PDCD5 and internal control actin proteins in heart extracts from 8–week-old male mice with sham or Ang II treatment. (E), Quantitative analysis
revealed that PDCD5 levels were up-regulated in hearts from mice treated with Ang II (n=4) as compared to sham control mice (n=4). *P,0.05,
sham vs. Ang II treatment.
doi:10.1371/journal.pone.0030097.g001
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transgenic mice results in reduced survival
High PDCD5 over-expressing line was born at Mendelian ratio.
However, the transgenic mice started to die at the age of 3 weeks,
and few were able to survive to six months of age (Fig. 3B). No
difference in survival was shown between male and female mice.
Mice dissection performed on anesthetized moribund mice
showed obvious pulmonary edema, elevated lung weight normal-
ized to body weight and enlarged hearts as compared to WT
littermate control mice (Figure S4A–B), indicating transgenic mice
developed heart failure.
High PDCD5 over-expressing line develops dilated
cardiomyopathy and heart failure
We next investigated cardiac pathology in high over-expressing
line. The heart-to-body weight ratio was significantly increased in
mice (Fig. 4A–B), with no significant difference in body weight
between transgenic mice and age-matched WT control (data not
shown). Accordingly, morphological analysis showed individual
cardiomyocyte was significantly larger in transgenic mice com-
pared to WT control mice (Fig. 4C), suggestive of cardiac
remodeling. Hematoxylin and Eosin (HE) staining showed
reduced thickness of ventricular walls, dilated heart chambers
and evidence of disarray of cardiomyocytes in ventricles of
transgenic hearts (Fig. 4D, Figure S4B). Masson trichrome staining
showed collagen deposition, a hallmark of cardiac hypertrophy
and heart failure, was significantly increased in transgenic mice
(Fig. 4E). Consistent with this finding, Real-Time RT-PCR
revealed significant increase in TGF-B, type I collagen, type III
collagen mRNA expression (data not shown). Although the fetal
gene program such as ANF, brain natriuretic peptide (BNP),
skeletal a-actin (SAA), a molecular marker of cardiac hypertrophy
and heart failure, barely detectable in hearts from WT control
mice, was expressed at considerable levels in transgenic hearts
(Fig. 4F–H). Moreover, increase in bMHC mRNA expression was
associated with decrease in alpha myosin heavy chain (aMHC)
mRNA expression (Fig. 4I–J), indicating a shift in myosin heavy
chain from alpha to beta isoform in transgenic hearts. In addition,
the sarcoplasmic/endoplasmic reticulum calcium ATPase
(SERCA), an established molecular marker of heart failure, was
significantly reduced in transgenic hearts (Fig. 4K). To further
determine the alteration of cardiac structure and cardiac function
of transgenic mice, we performed echocardiography on mice at 3
Figure 2. Generation of transgenic mice with cardiac specific over-expression of hPDCD5. (A), Schematic representation of the transgene
construct of hPDCD5 cDNA under the control of the cardiac-specific alpha-MHC promoter (not at scale). (B), Representative western blot of hPDCD5
protein with PDCD5 antibody in heart extracts from high over-expressing line and WT control mice. Asterisk indicates endogenous PDCD5. (C),
Densitometric analysis of PDCD5 immunoblots. (D), Representative western blot of hPDCD5 protein with HA antibody in heart extracts obtained from
high over-expressing line and WT control mice. (E), Representative western blot of hPDCD5 protein with HA antibody in heart, liver, and brain extracts
obtained from high over-expressing line and WT control mice.
doi:10.1371/journal.pone.0030097.g002
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(LVID;d) and LV end-systolic diameter (LVID;s) were greater as
compared to WT control mice (Fig. 5A–C). Left ventricular
posterior wall thickness (diastole) (LVPW;d) was significantly
reduced (Fig. 5D), suggesting the hearts were dilated in transgenic
mice. LV function was severely impaired in transgenic mice as
attested by a 65% decline in percent fractional shortening (FS%)
(Fig. 5E) and a 75% reduction in ejection fraction (EF) (Fig. 5F),
demonstrating transgenic mice developed heart failure. Consistent
with these findings, Lung weight normalized to body weight was
significantly increased in transgenic mice compared to WT control
mice, indicative of lung congestion (data not shown). Taken
together, high PDCD5 over-expressing line developed dilated
cardiomyopathy and heart failure.
Autophagy is up-regulated in high over-expressing line
Previously, PDCD5 has been shown to suppress growth of
multiple types of cancer cells by promoting apoptosis [2–4]. To
examine whether PDCD5 induces apoptosis in heart, we
performed TUNEL staining on cryosection of hearts from 3-
month-old mice. Surprisingly, the number of TUNEL-positive
cells remained unaltered in transgenic mice as compared to WT
littermate control mice (Fig. 6A–B). We then conducted Western
blot to detect apoptosis related gene expression. Bcl-2 didn’t show
significant change in transgenic mice, while Bax and Bax to Bcl-2
ratio were significantly up-regulated in transgenic hearts (Fig. 6C–
D). However, Cleaved caspase 3, a downstream executor of
apoptosis, was not significantly increased in transgenic mice of
different ages as compared to littermate control (Fig. 6C, 6E–F).
These data suggest that apoptosis is not likely the causative reason
for dilated cardiomyopathy in high PDCD5 over-expressing line.
As multiple lines of evidence suggest that autophagy is a major
mechanism for certain forms of heart disease [18–20], we
performed immunohistochemistry on paraffin section to detect
autophagy associated protein LC3 II. As expected, LC3 puncta
were dramatically increased in 3-month-old transgenic mice
(Fig. 7A–B). Accordingly, western blot showed LC3 II to LC3 I
processing, a molecular marker for autophagy, was significantly
increased in transgenic mice (Fig. 7C–D). Lysosomal-associated
membrane protein-1 (LAMP-1) and Cathepsin D, two markers for
Figure 3. The effect of hPDCD5 over-expression on the survival of mice. (A), Autopsy of transgenic founder 41 showing dramatically
enlarged heart. (B), Kaplan-Meier Survival Curves of high over-expressing line (red line) and WT littermate controls (black line). (n=50 for WT, n=65
for TG).
doi:10.1371/journal.pone.0030097.g003
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months of age (Fig. 7C), confirming the increased autophagic
activity in transgenic mice. Furthermore, time course analysis by
western blot using LC3 antibody showed that autophagic activity
remained elevated in mice at 2 weeks to 6 months of age (Fig. 7E),
suggesting the essential role of autophagy in the development of
dilated cardiomyopathy.
To determine the potential mechanism of autophagy activation
by PDCD5 over-expression, we examined the protein level of
acetylated p53 and its downstream target damage-regulated
autophagy modulator (DRAM). PDCD5 was shown to activate
p53, which plays dual roles in autophagy depending on the context
and subcellular localization [23]. Nucleus p53 can induce
autophagy via transcriptional effects including transactivation of
DRAM gene [24], while cytoplasmic p53 represses autophagy
through poorly-understood mechanisms [25]. As shown in Fig. 7F,
acetylated p53 at lysine 120 and DRAM were significantly up-
regulated by PDCD5 over-expression in heart. Taken together,
these data demonstrate that autophagy is significantly up-regulated
possibly through p53 activation in high PDCD5 over-expressing
transgenic mice. However, the precise molecular mechanisms of
autophagy regulation by PDCD5 remain to be elucidated.
Figure 4. Cardiac remodeling in high PDCD5 over-expressing line. (A), Cardiac specific high over-expression of hPDCD5 results in enlarged
hearts (3 months old). (B), HW:BW ratio showing significant increase in cardiac mass in high over-expressing line compared to the WT control mice
(n=6 for TG, n=6 for WT). (C), Measurement of two-dimensional cardiomyocyte cross-sectional area showing significantly enlarged cells in high over-
expressing line compared with WT control mice (n=4 for TG, n=4 for WT). *P,0.05, WT vs. TG. (D), Histological analysis with H&E staining on heart
sections. Bar, 50 mm. (E), Masson’s trichrome staining showing collagen depositon in left ventricle of high over-expressing line. Bar, 50 mm. Expression
of ANF (F), BNP (G), SAA (H), aMHC (I), bMHC (J) and SERCA (K) was determined by quantitative Real-Time RT-PCR analysis in cDNA samples derived
from heart of high over-expressing line and WT control mice (n=4 for TG, n=4 for WT). Expression levels were normalized to GAPDH. Experiments
were performed twice in triplicate with similar results. *P,0.05, WT vs. TG.
doi:10.1371/journal.pone.0030097.g004
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Ang II-induced cardiac hypertrophy
Given that PDCD5 is upregulated in hypertrophied heart and
high over-expressing line develops dilated cardiomyopathy and
heart failure, we hypothesized that low over-expressing line may be
more susceptible to Ang II-induced cardiac hypertrophy. To test
thishypothesis, we challengedthe lowover-expressingline with Ang
II for 2 weeks. The Ang II-infused transgenic mice showed
increased LV to BW ratio and enlarged cross-sectional area of
individual cardiomyocyte as compared to WT control mice
undergoing identical treatment (Fig. 8A–C). Systolic function
measured as FS% was not significantly changed in Ang II-treated
transgenic mice (Fig. 8D). These results suggest that low over-
expressing line is predisposed to Ang II-induced cardiac hypertro-
phy without attenuating cardiac function. In addition, LC3
processing was increased in heart of Ang II-treated transgenic mice
(Fig. 8E–F), implicating a role of autophagy in the susceptibility to
Ang II-induced cardiac hypertrophy in transgenic mice.
Discussion
The major findings in the present study are that (1) PDCD5
expression is significantly up-regulated in cardiac hypertrophy; (2)
Cardiac specific high over-expression of hPDCD5 results in
dilated cardiomyopathy, heart failure and premature sudden
death; (3) Autophagy is dramatically up-regulated in transgenic
mice with high hPDCD5 over-expression, which is associated with
increased p53 activity; (4) Low PDCD5 over-expressing line is
more susceptible to Ang II-induced cardiac hypertrophy.
PDCD5 in dilated cardiomyopathy and heart failure
Previous study demonstrated that PDCD5 mRNA is expressed
at an appreciable level in adult hearts [1], suggesting PDCD5 may
play an important role in heart. We showed that PDCD5 was
strongly induced upon Ang II treatment or transverse aortic
constriction, which has never been studied before, indicating the
potential role of PDCD5 in cardiac remodeling and cardiac
function. Indeed, high PDCD5 over-expression (10 fold) led to
autophagy activation, dilated cardiomyopathy and sudden death.
In addition, autopsy revealed that heart from the transgenic
founder died spontaneously was enlarged in both atria and
ventricles. On the basis of the phenotypes we observed in the
founder and high over-expression line, dilated cardiomyopathy
and heart failure in transgenic mice were not likely caused by
disruption of endogenous gene(s).
Autophagy activation in cardiac remodeling
A growing body of evidence showed that autophagy is involved
in the pathogenesis of cardiac diseases and plays distinct roles
depending on the context and dosage [18–20]. For instances,
cardiac autophagy is activated in response to pressure overload
and contributes to the transition from stable cardiac hypertrophy
to heart failure [29]. In ischemia-reperfusion injury, autophagy is
up-regulated. In the phase of ischemia, autophagy is beneficial,
while during perfusion autophagy is detrimental to the heart by
triggering cardiomyocytes apoptosis [30–31]. In a desmin-related
cardiomyopathy mouse model, autophagy is up-regulated and
beneficial to the cardiac function [32]. A recent study demon-
strated that autophagy contributes to the pathology of diabetic
Figure 5. Echocardiographic analysis of cardiac function of high over-expressing line. (A), Representative M-mode echocardiography
images in 3-month-old mice. (B)–(C), LV end-diastolic diameter (LVID;d) and LV end-systolic diameter (LVID;s) were significantly increased in high
over-expressing line compared to WT control mice. (D), Left ventricular posterior wall (LVPW) was significantly decreased in high over-expressing line
compared to WT control mice. (E)–(F), % fractional shortening and ejection fraction were significantly diminished in high over-expressing line
compared to WT control mice. *P,0.05, WT vs. TG (n=5 for TG, n=5 for WT, 3 months old).
doi:10.1371/journal.pone.0030097.g005
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autophagy was dramatically up-regulated, with significant increase
in autophagosomes, LC3 processing and cathepsin D, LAMP-1
protein abundance. Moreover, Beclin 1, a yeast atg6 homologue in
mammalian cells [34], was up-regulated in PDCD5 transgenic
heart. It has been indicated that increased autophagy accompa-
nied by elevated Beclin 1 protein levels may cause cell death [35–
36]. While we barely detected apoptotic cells, autophagy may be
the major mechanism of the pathogenesis of dilated cardiomyop-
athy and heart failure in high over-expressing line. We cannot
exclude the possibility that autophagy is adaptive at early stages of
development of heart failure in our transgenic mice model.
However, we find no evidence of accumulation of intracellular
protein aggregates and poly-ubiquitinated proteins (Figure S5),
which are normally toxic and protected by induced autophagy in
heart [32–33,37–39]. In low over-expressing line, autophagy
Figure 6. Assessment of apoptosis in high over-expressing line. (A), Representative images of TUNEL staining (green) and DAPI staining
(blue) for nuclei on cryosectioned hearts from 3-month-old high over-expressing line and WT control mice. B, Quantification of TUNEL staining
positive cells (30 microscopic fields from 3 mice for TG or WT). C, Representative western blot of apoptosis-related proteins Bcl-2, Bax and cleaved
caspase 3 in heart extracts obtained from 3-month-old high over-expressing line and WT control mice. (D), Densitometric analysis of Bax and Bcl-2
immunoblots. (E), Densitometric analysis of cleaved caspase 3 immunoblots. (F), Representative western blot of time course analysis of cleaved
caspase 3 in heart extracts obtained from high over-expressing line and WT control mice. *P,0.05, WT vs. TG.
doi:10.1371/journal.pone.0030097.g006
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months of age (Figure S6A). Beclin 1 wasn’t elevated in the low-
expressing line (Figure S6B). However, autophagy is up-regulated
in response to Ang II treatment in low over-expressing line,
indicating its involvement in cardiac remodeling. Considering Ang
II-treated low over-expressing line manifests no abnormalities of
cardiac function, the increased autophagy may be adaptive.
Indeed, Ang II-treated low over-expressing line shows less
autophagy than high over-expressing line, consistent with the
notion that autophagy beyond certain threshold is detrimental
[19,21]. However, increased autophagic activity could be
maladaptive and cardiac function could be deteriorated in low
over-expressing line in response to long-term Ang II infusion. This
remains to be determined by future study.
p53 and autophagy
One remaining question is how autophagy is activated in high
PDCD5 over-expressing line and Ang II-treated low over-
expressing line, but not normal low over-expressing line. PDCD5
is initially identified as a tumor suppressor, which inhibits cell
growth in a variety of cancer cells by inducing apoptosis [2–3]. In
cancer cells, PDCD5 interacts with Tip60, which activates p53, a
regulator playing dual roles in autophagy depending on the
context and subcellular localization [20–21]. Nucleus p53 function
Figure 7. Assessment of autophagy in high over-expressing line. (A), Representative images of Immunostaining of LC3 on paraffin section of
hearts from high over-expressing line and WT control mice. (B), Quantification of LC3 positive dots (For each group, 4 mice were studied). (C),
Representative western blot of autophagy-related proteins LC3, Beclin 1, LAMP-1 and cathepsin D in heart extracts obtained from 3-month-old high
over-expressing line and WT control mice. (D), Densitometric analysis of LC3 immunoblots. (E), Representative western blot of time course analysis of
LC3 processing in heart extracts obtained from high over-expressing line and WT control mice. (F), Representative western blot of acetylated p53 and
DRAM.
doi:10.1371/journal.pone.0030097.g007
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autophagy related genes. On the other hand, cytoplasmic p53
represses autophagy through poorly-characterized mechanisms
[30–32]. Thus, p53 may be involved in autophagy activation in
our transgenic mice model. Indeed, acetylated p53 at lysine 120
was increased in high over-expressing line. Moreover, DRAM, a
p53 downstream target, was up-regulated in high over-expressing
line, Thus, PDCD5 may induce autophagy via activating p53 in a
dose-dependent way. Additional work is required to establish the
direct link between PDCD5 level and degree of p53-mediated
autophagy activation. Interestingly, despite elevated p53 protein
abundance and increase in Bax/Bcl-2 ratio, an index of cell
susceptibility to apoptosis [40], we barely detected apoptotic nuclei
with TUNEL staining assay in high over-expressing line.
Consistent with this finding, cleaved caspase 3, a major
downstream apoptosis executor, was not significantly increased.
The lack of apoptosis may be attributed to the incomplete
apoptotic program in cardiomyocyte [41–42].
Figure 8. Susceptibility of low over-expressing line to Ang II-induced cardiac hypertrophy. (A), H&E staining on heart sections. Bar,
40 mm. (B), Measurement of two-dimensional cardiomyocyte cross-sectional area. (C), LV to BW ratio is significantly increased in Ang II- treated
transgenic mice as compared to WT control mice receiving identical treatment. (D), In transgenic mice treated with Ang II, FS% is not significantly
altered as compared to WT control mice. (E), Representative images of LC3 processing in Ang II-treated transgenic mice and WT control mice. (F)
Densitometric analysis of LC3 immunoblots. *P,0.05, WT vs. TG (n=4–5 for each group).
doi:10.1371/journal.pone.0030097.g008
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In conclusion, PDCD5 is upregulated in the development of
cardiac hypertrophy. We generated cardiac specific PDCD5
transgenic mice to determine the role of PDCD5 in cardiac
remodeling and function. High over-expression of human PDCD5
leads to dilated cardiomyopathy and sudden death. This is
attributed at least in part to elevated autophagic activity, which is
associated with increased activity of p53. Low over-expression of
human PDCD5 is more susceptible to Ang II-induced cardiac
hypertrophy. It will be interesting to further examine the function
and decipher the precise molecular mechanisms of PDCD5 in
cardiac hypertrophy and heart failure using loss-of-function
method. It also will be interesting to investigate the function of
PDCD5 in other cardiac diseases such as ischemic heart disease.
Materials and Methods
Ethics Statement
All animal experimentation in this study was conducted in
accordance with the National Research Council Guide for Care
and Use of Laboratory Animals, with the approved protocols by
the Institutional Animal Care and Use Committee of Shanghai,
China [SYXK (SH) 2011-0112]. Efforts were made to minimize
suffering.
Reagents
Mouse anti actin (Sigma), rabbit anti LC3 (MBL), rabbit anti
Bcl-2 (Cell Signaling), mouse anti acetylated p53 (Abcam), rat anti
LAMP-1 (Santa Cruz), rabbit anti Cathepsin D (Santa Cruz),
rabbit anti cleaved caspase 3 (Cell Signaling), rabbit anti Bax (Cell
Signaling), rabbit anti DRAM (Abcam), Cy3-conjugated goat anti
rabbit (Jackson ImmunoResearch), cy3-conjugated goat anti-
mouse (Jackson ImmunoResearch), rat anti-HA (Roche Applied
Sciences), rabbit anti Beclin 1(MBL), rabbit anti ubiquitin (Sigma).
Chronic Ang II infusion
Eight-week-old C57BL/6 mice were infused with Ang II
(n=15) or saline (n=12) for 14 days via osmotic minipumps
(model 2002; Alzet). The osmotic minipumps were implanted
subcutaneously, slightly posterior to the scapula. Ang II was
dissolved in 0.5 mol/l NaCl and 1 mmol/l acetic acid and infused
at a rate of 2.16 mg/kg/day.
Transverse aortic constriction (TAC)
Seven-week-old male mice were subjected to transverse aortic
constriction (TAC) for 2 weeks as described previously [29,43].
Transgenic mice and genotyping
Human influenza hemagglutinin (HA) epitope tagged full length
human PDCD5 cDNA was PCR amplified from the expressing
construct PCDB-PDCD5 and cloned into alpha myosin heavy
chain promoter plasmid. The plasmid was digested with Not I,
generating a fragment containing the a-MHC promoter, HA-
tagged hPDCD5 cDNA, and human growth hormone polyA,
which was purified and microinjected into the pronuclei of
C57BL/6 mouse eggs. The eggs were then implanted into the
oviducts of pseudo-pregnant recipients. Genotyping for Transgen-
ic founders were performed by PCR analysis of mouse tail DNA
and the primers used were as follows: forward primer; 59-
GGCGCTGAGGAGACAGAG-39, reverse primer: 59-GTCTT-
CCGTACAGGATGGACGTG-39. Five founders identified by
PCR genotyping were bred with C57BL/6 mice. Generation of
transgenic mice was performed in Model Animal Research Center
of Nanjing University.
Western blot
Mouse hearts were homogenized in lysis buffer and the lysates
were collected and quantified with NanodropH. Proteins were
separated in a SDS-PAGE gel and transferred to nitrocellulose
membrane. The membrane was then blocked for 1 hour at room
temperature with 5% non fat milk in tris buffered saline containing
0.1% Tween (TBST), probed with primary antibody overnight at
4uC, washed with TBST three times, and incubated with
secondary antibody for 1 hour at room temperature, washed
again with TBST three times. Immunolabeled proteins were then
revealed by using ECL Plus (GE Healthcare).
Histology
Mouse hearts were perfusion washed with PBS and fixed with
ice cold 4% paraformaldehyde in PBS. Hearts embedded in
paraffin were cut into serial 5 mm sections (Leica RM2255 rotary
microtome) and stained with H&E or Masson trichrome to
evaluate morphology and cellular dimensions. Hearts for TUNEL
staining were cryoprotected in 30% sucrose overnight and
embedded in freezing matrix. Serial 8 mm cryostat sections were
prepared (Leica CM3050S cryostat) and stored at 280uC until
use. TUNEL assays were performed with the In Situ Cell Death
Detection Kit (Roche Applied Science) according to the
manufacturer’s instructions. The sections were counterstained
with DAPI.
Immunostaining
Tissues were permeabilized with 0.3% Triton X-100 in 16PBS
(PBST) for 30 min and then blocked with 0.3% horse serum in
BSA in PBST for 1 h. Sample were incubated overnight with
primary antibody at 4uC, washed with PBST 3 times, and
incubated with cy3-conjugated goat anti-rabbit IgG for 1 hour at
room temperature in the dark and were washed with PBST. DAPI
staining was performed as counterstaining.
Cardiomyocyte cross-sectional area
The cross-sectional area of cardiomyocytes was measured by
H&E staining with image analysis software (Image J) and
calculated as the mean of 120–150 cells from randomly selected
fields.
RNA isolation and Real-Time RT-PCR
Total RNA was prepared from hearts of WT and transgenic
mice using TRIZOLH reagent, and cDNA was synthesized using
Superscript IIIH reverse transcriptase (RT) (Invitrogen). mRNA
expression was analyzed by quantitative Real-Time RT-PCR
(Applied Biosystems StepOne Plus
TM) and were normalized to
GAPDH housekeeping gene. Real-time RT-PCR was performed
in triplicate for each sample. The primers used for Real-Time RT-
PCR are shown in Table 1.
Echocardiography
Echocardiography was performed on mice anesthetized with
isoflurane. Echocardiographic imaging was conducted using a
Vevo 770 platform (VisualSonics, Canada). Measurements were
carried out at least in triplicate. The parameters measured were as
follows: Heart rate, LVID;d; LVID;s; left ventricular posterior wall
thickness (diastole) (LVPW;d) and EF. FS% was calculated as
follows: FS%=(LVID;d–LVID;s)/LVID;d6100%.
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All values were expressed as mean 6 SD. Data were analyzed
using Student’s t-test and significance was considered with
P,0.05.
Supporting Information
Figure S1 Up-regulation of PDCD5 in acute pressure
overload-induced cardiac hypertrophy. (A), HW:BW ratio
showing significant increase in cardiac mass in mice subjected to
TAC for 2 weeks compared to sham-operated control mice. (B),
Representative western blot of PDCD5 and internal control actin
proteins in heart extracts from 7–week-old male mice subjected to
TAC or sham surgery.
(TIF)
Figure S2 Enhanced PDCD5 mRNA level in heart from
high over-expressing line. PDCD5 mRNA was determined by
quantitative Real-Time RT-PCR analysis in cDNA samples
derived from heart of transgenic line 32 and WT control mice.
Expression levels were normalized to GAPDH. Experiments were
performed twice in triplicate with similar results. *P,0.05, WT vs.
TG.
(TIF)
Figure S3 Characterization of low over-expressing line.
(A) Representative western blot of hPDCD5 protein in heart
extracts from high and low over-expressing line. (B), Hearts from
low over-expressing line exhibiting similar size as compared to non
transgenic littermate control mice (6 months old). (C), HW:BW
ratio of 6-month-old mice showing no significant difference in
cardiac mass between low PDCD5 expressing line as compared to
the non transgenic littermate control mice (n=7 for TG, n=6 for
WT).
(TIF)
Figure S4 Enlarged heart from 3-week-old high over-
expressing line. (A), High over-expression of hPDCD5 in the
transgenic mice results in enlarged hearts. (B), Hematoxylin and
eosin staining of the heart from high over-expressing line and non-
transgenic littermate control mice.
(TIF)
Figure S5 Detection of accumulation of protein aggre-
gates in high over-expressing line. (A), Representative
immunohistochemistry images of time course analysis of ubiqui-
tinated protein aggregates in heart section from high over-
expressing line and WT control mice. (B), Representative western
blot of time course analysis of poly-ubiquitinated protein in heart
extracts obtained from high over-expressing line and WT control
mice.
(TIF)
Figure S6 Autophagy in low over-expressing line. (A),
Representative western blot of time course analysis of LC3
processing in heart extracts obtained from low over-expressing line
and WT control mice. (B), Representative western blot of time
course analysis of Beclin 1 protein in heart extracts obtained from
low over-expressing line and WT control mice.
(TIF)
Table S1 Echocardiographic data for low over-expressing line.
Results from echocardiography in low over-expressing line and
WT control. Data presented as mean6 SD, n=5 in each group.
LVID;d, left-ventricular internal diameter at diastole; LVPW;d,
left-ventricular posterior wall at diastole; LVID;s, left-ventricular
internal diameter at systole; LVPW;s, left-ventricular posterior
wall at systole; LVAW;d, left ventricular anterolateral wall at
diastole; LVAW;s, left ventricular anterolateral wall at systole;
FS%, percent fractional shortening; EF, ejection fraction.
(DOC)
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